Polyclonal Antibody Allergen Binding Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current strategies for reducing or preventing allergies caused by environmental allergens, such as Fel D1 from cats, are either invasive, expensive, or impractical, and existing treatments do not effectively minimize exposure to these allergens in everyday environments.
Innovation Solution
A polyclonal antibody composition that inhibits the ability of allergens like Fel D1 to bind to mast cells is used, either by contacting the allergen source directly or through edible forms administered to animals that disseminate the allergens, thereby reducing allergic responses in sensitive individuals.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If avoidance strategies are used to reduce allergen exposure, then allergic symptoms are reduced, but complete avoidance is not practical and requires significant time and expense
Solution Approach 1:
The patent introduces an intermediary substance (allergen-binding agent or tolerance-inducing composition) that mediates between the allergen and the allergic individual. This agent binds to the allergen to prevent direct interaction with the immune system, or induces tolerance through controlled exposure, making allergen avoidance unnecessary while still reducing allergic symptoms
Solution Approach 2:
The patent employs strategies where the allergic individual's own immune system is harnessed to reduce sensitivity. Through tolerance-inducing therapies, the immune system is retrained to recognize and tolerate the allergen, enabling the individual to withstand allergen exposure without experiencing severe allergic reactions
2Object-affected harmful factors
If tolerance strategies such as allergen immunotherapy are used, then long-term tolerance is established, but treatment is expensive, invasive, time-consuming, and requires expert administration
Solution Approach 1:
The patent employs simpler, more accessible treatment formulations that can be administered without requiring complex medical infrastructure or expert supervision. These may include oral formulations, nasal sprays, or topical applications that are easier and less expensive to administer than traditional injectable immunotherapies
Solution Approach 2:
The patent extracts or isolates specific allergen components or uses purified allergen preparations that can be safely administered through simpler routes. By focusing on key allergenic proteins or using modified allergen structures, the treatment achieves efficacy while reducing complexity and risk
3Object-affected harmful factors
If traditional avoidance or tolerance strategies are used, then allergic responses are managed, but these strategies do not effectively minimize exposure to allergens in everyday environments
Solution Approach 1:
The patent develops compositions or strategies that work across multiple allergen types and exposure scenarios. A single intervention can address different allergens (pet dander, pollen, mold) and different routes of exposure (inhalation, contact, ingestion), providing reliable protection in diverse everyday environments without requiring multiple specialized treatments
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of polyclonal antibodies effectively minimizes allergic reactions by preventing allergen binding to mast cells, offering a practical and cost-effective solution for reducing exposure to environmental allergens in everyday environments.
Implementation Method 1
a polyclonal antibody that inhibits the ability of the allergen Fel D1 to bind to mast cells
Data Source
AI summary
Compositions suitable for reducing symptoms of an allergic response to environmental allergens comprising molecules that specifically inhibit the ability of the allergen to bind to mast cells in an animal predisposed to having an allergic response to the allergen and methods for reducing such symptoms comprising contacting a source of the environmental allergen with such compositions. Kits, packages, medicaments, and means of communicating about the compositions and methods are also provided.